Latest Definium Therapeutics News & Updates

See the latest news and media coverage for Definium Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Definium Therapeutics

Psychedelic medicine company for brain health disorders

definiumtx.com

Headquarters: New York, United States
Founded year: 2019
Company type: Public company
Number of employees: 125–200

Last updated Today

Latest news about Definium Therapeutics

In short: Definium Therapeutics rebranded from MindMed and reported positive Phase 3 results for its LSD therapy in treating major depressive disorder.

Company announcements

Yesterday Definium Therapeutics

Definium Therapeutics announces proposed public offering of $500 million common shares

The company plans to use proceeds for R&D, potential commercialization of DT120 ODT, and working capital.

Yesterday Definium Therapeutics

Definium Therapeutics will discuss Phase 3 Emerge topline results on June 22

The company will host a webcast at 8 a.m. EDT to present results from the Phase 3 study of DT120 ODT in major depressive disorder.

June 15 Definium Therapeutics

Definium Therapeutics announces new employee inducement grants

Inducement grants of options to purchase 155,480 shares were issued to six non-executive employees, vesting over four years.

May 12 Definium Therapeutics

Definium Therapeutics doses first patient in Phase 3 MDD study

The Ascend study evaluates DT120 ODT versus placebo in 175 participants, with topline data expected in 2027.

Media coverage

Yesterday Business Wire

Definium Therapeutics, Inc. Announces Proposed Public Offering

Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of ther...

June 21 Bloomberg

Psychedelics Drug Developer Definium Surges on Depression Trial Data - Bloomberg

Definium Therapeutics Inc. shares rally as much as 60% Monday after late-stage trial data showed “groundbreaking” results in the psychedelic drug developer’s experimental treatment for...

May 9 Seeking Alpha

Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call Transcript

Good afternoon. I am Gita Jain, Head of Investor Relations, and thank you for joining us today for Definium Therapeutics First Quarter 2026 Financial Results...

February 3 Law360

Pharma Co. Stole Secrets For LSD Medical Trials, Suit Says - Law360

A clinical trial services company is suing Definium Therapeutics Inc. in Delaware federal court, alleging that it stole trade secrets during Phase 2 trials of...

Never miss news about Definium Therapeutics

Track Definium Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.